TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT07551544

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“Sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

202620272028Registered2026-04-20Planned start2026-05-15 (planned)Withdrawn (as of)2026-05-19

Vital statistics

Status
Withdrawn
Phase
Phase 3
Sponsor
ImmunityBio, Inc.
Sponsor type
Industry
Conditions
NMIBC
Interventions
BCG (50 mg) plus ANKTIVA (400 µg); BCG (50 mg)
Participants
0

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.